Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prapassorn Thirasastr

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Clinical and Experimental Gastroenterology|February 17, 2023
Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal TumorsPrapassorn Thirasastr, Neeta Somaiah
Therapeutic Advances in Medical Oncology|March 7, 2022
Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcomaPrapassorn Thirasastr, Neeta Somaiah
Current Treatment Options in Oncology|February 28, 2023
Myxoid Liposarcomas: Systemic Treatment OptionsElise F Nassif, Emily Z Keung, Prapassorn Thirasastr, et al.
Surgical Oncology Clinics of North America|June 17, 2022
New Drug Approvals for Sarcoma in the Last 5 YearsPrapassorn Thirasastr, Mehdi Brahmi, Armelle Dufresne, et al.
Anticancer Research|December 8, 2019
Feasibility Technique of Low-passage <i>In Vitro</i> Drug Sensitivity Testing of Malignant Pleural Effusion from Advanced-stage Non-small Cell Lung Cancer for Prediction of Clinical OutcomeChanida Vinayanuwattikun, Ornjira Prakhongcheep, Sucharat Tungsukruthai, et al.
Frontiers in Oncology|February 27, 2023
Case report: Responses to the combination of gemcitabine with sirolimus in two patients with <i>TSC</i>-mutated sarcomasElise F Nassif, Cissimol P Joseph, Rossana Lazcano, et al.
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
Cancer Medicine|September 24, 2022
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcomaPrapassorn Thirasastr, Heather Lin, Behrang Amini, et al.
Cell Reports. Medicine|February 18, 2026
Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancerZecheng Yang, Madelaine S Theardy, Shuaitong Chen, et al.
Cancers|March 13, 2024
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinical and Experimental Gastroenterology|February 17, 2023
Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal TumorsPrapassorn Thirasastr, Neeta Somaiah
Therapeutic Advances in Medical Oncology|March 7, 2022
Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcomaPrapassorn Thirasastr, Neeta Somaiah
Current Treatment Options in Oncology|February 28, 2023
Myxoid Liposarcomas: Systemic Treatment OptionsElise F Nassif, Emily Z Keung, Prapassorn Thirasastr, et al.
Surgical Oncology Clinics of North America|June 17, 2022
New Drug Approvals for Sarcoma in the Last 5 YearsPrapassorn Thirasastr, Mehdi Brahmi, Armelle Dufresne, et al.
Anticancer Research|December 8, 2019
Feasibility Technique of Low-passage <i>In Vitro</i> Drug Sensitivity Testing of Malignant Pleural Effusion from Advanced-stage Non-small Cell Lung Cancer for Prediction of Clinical OutcomeChanida Vinayanuwattikun, Ornjira Prakhongcheep, Sucharat Tungsukruthai, et al.
Frontiers in Oncology|February 27, 2023
Case report: Responses to the combination of gemcitabine with sirolimus in two patients with <i>TSC</i>-mutated sarcomasElise F Nassif, Cissimol P Joseph, Rossana Lazcano, et al.
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
Cancer Medicine|September 24, 2022
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcomaPrapassorn Thirasastr, Heather Lin, Behrang Amini, et al.
Cell Reports. Medicine|February 18, 2026
Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancerZecheng Yang, Madelaine S Theardy, Shuaitong Chen, et al.
Cancers|March 13, 2024
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, et al.
Pageof 2